Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13207121 | 0.94 | CARM1 (0.43) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13010016 | 0.92 | PTGER1 (0.46) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13009991 | 0.91 | CARM1 (0.40) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13010015 | 0.89 | PTGER1 (0.44) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13009661 | 0.87 | PTGER1 (0.55) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13009638 | 0.86 | PTGER1 (0.44) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13010001 | 0.86 | PTGER4 (0.52) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13009719 | 0.86 | PTGER1 (0.54) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL13010004 | 0.85 | CARM1 (0.43) | CARM1PRMT1PTGER1PTGER4PTGER3 | |
| SCHEMBL29748782 | 0.84 | PTGER1 (0.53) | PTGER1PTGER4PTGER3PTGER2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317854-A1 | NOVEL AMINODICARBOXYLIC ACID DERIVATIVES HAVING PHARMACEUTICAL PROPERTIES | DDC, AADAT, PTGIS | CARM1 2851/4885PRMT1 1880/4885PTGER1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.